# ONK Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onk-therapeutics

- Industry: Biotechnology
- Headquarters: Galway, Ireland
- Website: www.onktherapeutics.com
- Total disclosed funding: $22M
- Latest round: Series A (Jan 6, 2022)
- Investors on record: 3

## About

ONK Therapeutics Limited is focused on developing next-generation NK cell therapies, targeting both solid and hematological cancers through advanced engineering strategies for enhanced treatment efficacy.Founded in 2015 in Galway, Ireland, ONK Therapeutics Limited specializes in innovative NK cell therapies for cancer treatment. The company has successfully raised funding through Series A financing, securing USD 21.5 mn in January 2022 from investors including ALSHC and Acorn BioVentures. Co-founders Michael O'Dwyer and Tony Killarney have previously contributed to the biotechnology sector, with Chris Nowers currently serving as CEO. The firm has conducted two significant deals to date, with the latest occurring in January 2022.ONK Therapeutics specializes in next-generation, dual-targeted natural killer (NK) cell therapies, aimed at treating both solid and hematological cancers. The company's core product offerings revolve around optimally engineered off-the-shelf NK cell therapies that enhance cancer cell killing through advanced engineering strategies. These therapies are designed to improve tumor homing and persistence within the body while effectively addressing exhaustion within the tumor microenvironment. The end users of ONK Therapeutics' products primarily include oncology clinics, hospitals, and research institutions, which leverage these innovative therapies to provide advanced treatment options for patients battling various forms of cancer. The company actively engages with leading academic centers and clinical institutions across North America and Europe to advance scientific understanding and the clinical evaluation of its therapies.In 2021, ONK Therapeutics reported a revenue of USD 1,035,048.50. The company’s revenue generation is largely attributed to partnerships and collaborations with academic institutions, clinical entities, and industry partners, focusing on the advancement and commercialization of its NK cell therapies. ONK Therapeutics has established collaborative research agreements and development partnerships, which facilitate funding and shared intellectual property rights, integrating its therapies into existing cancer treatment protocols.Following the Series A financing round completed in January 2022, ONK Therapeutics Limited plans to utilize the USD 21.5 mn raised to advance its pre-clinical programs through comprehensive IND-enabling studies and in-vivo proof-of-concept models across multiple projects. The company is also focused on developing its GMP manufacturing capability and optimizing its proprietary cell engineering platform. As part of its growth strategy, ONK Therapeutics aims to expand into new markets and geographic regions, although specific locations and timelines have not been detailed.

## Funding rounds

- Series A, Jan 6, 2022, $22M — Cormorant Asset Management, Acorn Bioventures, ALSHC

## Investors

- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Acorn Bioventures (https://capitalatlas.ai/funds/acorn-bioventures) — Series A
- ALSHC — Series A